{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:42:23Z","timestamp":1792701743620,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,8,25]],"date-time":"2012-08-25T00:00:00Z","timestamp":1345852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s00415-012-6653-9","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T08:37:04Z","timestamp":1345797424000},"page":"1202-1214","source":"Crossref","is-referenced-by-count":74,"title":["Multiple sclerosis and pregnancy: therapeutic considerations"],"prefix":"10.1007","volume":"260","author":[{"given":"Maria K.","family":"Houtchens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channa M.","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,25]]},"reference":[{"key":"6653_CR1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/135245850000600207","volume":"6","author":"DT Grima","year":"2000","unstructured":"Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L (2000) Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 6:91\u201398","journal-title":"Mult Scler"},{"key":"6653_CR2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11532230-000000000-00000","volume":"28","author":"H Naci","year":"2010","unstructured":"Naci H, Fleurence R, Birt J, Duhig A (2010) Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 28:363\u2013379","journal-title":"Pharmacoeconomics"},{"key":"6653_CR3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.18553\/jmcp.2010.16.9.703","volume":"16","author":"CV Asche","year":"2010","unstructured":"Asche CV, Singer ME, Jhaveri M, Chung H, Miller A (2010) All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 16:703\u2013712","journal-title":"J Manag Care Pharm"},{"key":"6653_CR4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3111\/13696990903543085","volume":"13","author":"H Naci","year":"2010","unstructured":"Naci H, Fleurence R, Birt J, Duhig A (2010) The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ 13:78\u201389","journal-title":"J Med Econ"},{"key":"6653_CR5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","volume":"112","author":"BG Weinshenker","year":"1989","unstructured":"Weinshenker BG, Bass B, Rice GP et al (1989) The natural history of multiple sclerosis: a geographically based study I. Clinical course and disability. Brain 112:133\u2013146","journal-title":"Brain"},{"key":"6653_CR6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/brain\/103.2.281","volume":"103","author":"C Confavreux","year":"1980","unstructured":"Confavreux C, Aimard G, Devic M (1980) Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103:281\u2013300","journal-title":"Brain"},{"key":"6653_CR7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","volume":"339","author":"C Confavreux","year":"1998","unstructured":"Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med 339:285\u2013291","journal-title":"N Engl J Med"},{"key":"6653_CR8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/brain\/awh152","volume":"127","author":"S Vukusic","year":"2004","unstructured":"Vukusic S, Hutchinson M, Hours M et al (2004) Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127:1353\u20131360","journal-title":"Brain"},{"key":"6653_CR9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.clineuro.2005.11.016","volume":"108","author":"S Vukusic","year":"2006","unstructured":"Vukusic S, Confavreux C (2006) Pregnancy and multiple sclerosis: the children of PRIMS. Clin Neurol Neurosurg 108:266\u2013270","journal-title":"Clin Neurol Neurosurg"},{"key":"6653_CR10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/187152409788452054","volume":"9","author":"M Niino","year":"2009","unstructured":"Niino M, Hirotani M, Fukazawa T, Kikuchi S, Sasaki H (2009) Estrogens as potential therapeutic agents in multiple sclerosis. Cent Nerv Syst Agents Med Chem 9:87\u201394","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"6653_CR11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1600-0404.1994.tb02728.x","volume":"90","author":"E Stenager","year":"1994","unstructured":"Stenager E, Stenager EN, Jensen K (1994) Effect of pregnancy on the prognosis for multiple sclerosis: a 5-year follow up investigation. Acta Neurol Scand 90:305\u2013308","journal-title":"Acta Neurol Scand"},{"key":"6653_CR12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jnnp.2008.163816","volume":"81","author":"MB D\u2019hooghe","year":"2010","unstructured":"D\u2019hooghe MB, Nagels G, Uitdehaag BM (2010) Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry 81:38\u201341","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6653_CR13","unstructured":"National MS Society (2011) Pregnancy, delivery, and the postpartum period: information for women with MS to share with their physicians. http:\/\/www.nationalmssociety.org\/living-with-multiple-sclerosis\/healthy-living\/pregnancy\/index.aspx . Accessed 12 August 2011"},{"key":"6653_CR14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1191\/1352458504ms1083oa","volume":"10","author":"PK Coyle","year":"2004","unstructured":"Coyle PK, Christie S, Fodor P et al (2004) Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler 10:582\u2013588","journal-title":"Mult Scler"},{"key":"6653_CR15","first-page":"e332","volume":"17","author":"DB Davis","year":"2010","unstructured":"Davis DB (2010) Drugs in pregnancy\u2014the issues for 2010. J Popul Ther Clin Pharmacol 17:e332\u2013e335","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"6653_CR16","volume-title":"Medications and mothers\u2019 milk","author":"TW Hale","year":"2010","unstructured":"Hale TW (2010) Medications and mothers\u2019 milk, 14th edn. Hale Publishing, Amarillo","edition":"14"},{"key":"6653_CR17","unstructured":"Copaxone (glatiramer acetate) prescribing information (2011) http:\/\/www.sharedsolutions.com\/pdfs\/prescribinginformation.aspx . Accessed 4 November 2011"},{"key":"6653_CR18","unstructured":"Coyle P, Johnson K, Pardo L (2003) Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Milan, 17\u201320 September 2003"},{"key":"6653_CR19","first-page":"1","volume":"60","author":"SJ Ventura","year":"2012","unstructured":"Ventura SJ, Curtin SC, Abma JC (2012) Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990\u20132008. Nat Vital Statistics Rep 60:1\u201322","journal-title":"Nat Vital Statistics Rep"},{"key":"6653_CR20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1352458509106543","volume":"15","author":"C Weber-Schoendorfer","year":"2009","unstructured":"Weber-Schoendorfer C, Schaefer C (2009) Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 15:1037\u20131042","journal-title":"Mult Scler"},{"key":"6653_CR21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clineuro.2010.11.016","volume":"113","author":"A Finkelsztejn","year":"2011","unstructured":"Finkelsztejn A, Fragoso YD, Ferreira ML et al (2011) The Brazilian database on pregnancy in multiple sclerosis. Clin Neurol Neurosurg 113:277\u2013280","journal-title":"Clin Neurol Neurosurg"},{"key":"6653_CR22","first-page":"969","volume":"24","author":"YD Fragoso","year":"2010","unstructured":"Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR et al (2010) Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series. CNS Drugs 24:969\u2013976","journal-title":"CNS Drugs"},{"key":"6653_CR23","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1007\/s00415-010-5652-y","volume":"257","author":"HJ Salminen","year":"2010","unstructured":"Salminen HJ, Leggett H, Boggild M (2010) Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol 257:2020\u20132023","journal-title":"J Neurol"},{"key":"6653_CR24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00415-010-5758-2","volume":"258","author":"K Hellwig","year":"2011","unstructured":"Hellwig K, Gold R (2011) Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol 258:502\u2013503","journal-title":"J Neurol"},{"key":"6653_CR25","unstructured":"Rebif (subcutaneous interferon beta-1a) prescribing information (2011) http:\/\/www.emdserono.com\/cmg.emdserono_us\/en\/images\/rebif_tcm115_19765.pdf . Accessed 4 November 2011"},{"key":"6653_CR26","unstructured":"Avonex (intramuscular interferon beta-1a) prescribing information (2011) http:\/\/www.avonex.com\/pdfs\/pi-powder.pdf . Accessed 4 November 2011"},{"key":"6653_CR27","unstructured":"Betaseron (interferon beta-1b) prescribing information (2011) http:\/\/berlex.bayerhealthcare.com\/html\/products\/pi\/Betaseron_PI.pdf . Accessed 4 November 2011"},{"key":"6653_CR28","doi-asserted-by":"crossref","first-page":"P06.191","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P06.191","volume":"78","author":"S Richman","year":"2012","unstructured":"Richman S, Wallace K, Liu S, Sperling B (2012) Pregnancy outcomes from the Avonex\u00ae (interferon beta-1a) pregnancy exposure registry. Neurology 78:P06.191","journal-title":"Neurology"},{"key":"6653_CR29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1352458510394610","volume":"17","author":"M Sandberg-Wollheim","year":"2011","unstructured":"Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G (2011) Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 17:423\u2013430","journal-title":"Mult Scler"},{"key":"6653_CR30","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1212\/WNL.0b013e3181fd62bb","volume":"75","author":"MP Amato","year":"2010","unstructured":"Amato MP, Portaccio E, Ghezzi A et al (2010) Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology 75:1794\u20131802","journal-title":"Neurology"},{"key":"6653_CR31","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s00415-008-0909-4","volume":"255","author":"F Patti","year":"2008","unstructured":"Patti F, Cavallaro T, Lo Fermo S et al (2008) Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol 255:1250\u20131253","journal-title":"J Neurol"},{"key":"6653_CR32","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1212\/01.wnl.0000168905.97207.d0","volume":"65","author":"M Sandberg-Wollheim","year":"2005","unstructured":"Sandberg-Wollheim M, Frank D, Goodwin TM et al (2005) Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 65:802\u2013806","journal-title":"Neurology"},{"key":"6653_CR33","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/01.wnl.0000180575.77021.c4","volume":"65","author":"R Boskovic","year":"2005","unstructured":"Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G (2005) The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 65:807\u2013811","journal-title":"Neurology"},{"key":"6653_CR34","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00415-009-5376-z","volume":"257","author":"K Hellwig","year":"2010","unstructured":"Hellwig K, Haghikia A, Gold R (2010) Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol 257:580\u2013583","journal-title":"J Neurol"},{"key":"6653_CR35","unstructured":"Gilenya (fingolimod) US prescribing information (2011) http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gilenya.pdf . Accessed 4 November 2011"},{"key":"6653_CR36","unstructured":"Gilenya (fingolimod) European public assessment report (2012) http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002202\/human_med_001433.jsp&mid=WC0b01ac058001d124 . Accessed 22 June 2012"},{"issue":"Suppl 4","key":"6653_CR37","first-page":"A609","volume":"76","author":"W Collins","year":"2011","unstructured":"Collins W, Francis G, Koren G et al (2011) Lack of interaction between fingolimod (FTY720) and oral contraceptives, and pregnancy experience in the clinical program of fingolimod in multiple sclerosis. Neurology 76(Suppl 4):A609","journal-title":"Neurology"},{"key":"6653_CR38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/bdrb.20193","volume":"86","author":"NG Wehner","year":"2009","unstructured":"Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J (2009) Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol 86:144\u2013156","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"6653_CR39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/bdrb.20190","volume":"86","author":"NG Wehner","year":"2009","unstructured":"Wehner NG, Shopp G, Oneda S, Clarke J (2009) Embryo\/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol 86:117\u2013130","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"6653_CR40","unstructured":"Tysabri (natalizumab) prescribing information (2011) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125104s0658lbl.pdf . Accessed 6 December 2011"},{"key":"6653_CR41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/bdrb.20189","volume":"86","author":"NG Wehner","year":"2009","unstructured":"Wehner NG, Shopp G, Rocca MS, Clarke J (2009) Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs. Birth Defects Res B Dev Reprod Toxicol 86:98\u2013107","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"6653_CR42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/bdrb.20191","volume":"86","author":"NG Wehner","year":"2009","unstructured":"Wehner NG, Skov M, Shopp G, Rocca MS, Clarke J (2009) Effects of natalizumab, an alpha4 integrin inhibitor, on fertility in male and female guinea pigs. Birth Defects Res B Dev Reprod Toxicol 86:108\u2013116","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"6653_CR43","unstructured":"Tysabri (natalizumab) European public assessment report (2011) http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000603\/human_med_001119.jsp&mid=WC0b01ac058001d124 . Accessed 22 June 2012"},{"key":"6653_CR44","doi-asserted-by":"crossref","first-page":"S457","DOI":"10.1177\/1352458510389219","volume":"17","author":"LM Cristiano","year":"2011","unstructured":"Cristiano LM, Bozic C, Bloomgren G (2011) Preliminary evaluation of pregnancy outcomes from the Tysabri\u00ae (natalizumab) pregnancy exposure registry. Mult Scler 17:S457","journal-title":"Mult Scler"},{"key":"6653_CR45","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1600-0404.2010.01426.x","volume":"123","author":"IA Hoevenaren","year":"2011","unstructured":"Hoevenaren IA, de Vries LC, Rijnders RJ, Lotgering FK (2011) Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases. Acta Neurol Scand 123:430\u2013433","journal-title":"Acta Neurol Scand"},{"key":"6653_CR46","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1177\/1352458511401944","volume":"17","author":"K Hellwig","year":"2011","unstructured":"Hellwig K, Haghikia A, Gold R (2011) Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 17:958\u2013963","journal-title":"Mult Scler"},{"key":"6653_CR47","first-page":"S455","volume":"17","author":"A Mattioda","year":"2011","unstructured":"Mattioda A, Masera S, Romagnolo A et al (2011) Healthy baby delivery after conception during natalizumab exposure: a case report. Mult Scler 17:S455\u2013S456","journal-title":"Mult Scler"},{"key":"6653_CR48","first-page":"S227","volume":"17","author":"R Totaro","year":"2011","unstructured":"Totaro R, Rossi M, Casalena A, Carolei A (2011) Pregnancy, delivery, and birth outcome after natalizumab use for multiple sclerosis: a report of two cases. Mult Scler 17:S227\u2013S228","journal-title":"Mult Scler"},{"key":"6653_CR49","unstructured":"Novantrone (mitoxantrone) prescribing information (2011) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/019297s033s034lbl.pdf . Accessed 4 November 2011"},{"key":"6653_CR50","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.neuro.2006.10.002","volume":"28","author":"M Santis De","year":"2007","unstructured":"De Santis M, Straface G, Cavaliere AF, Rosati P, Batocchi AP, Caruso A (2007) The first case of mitoxantrone exposure in early pregnancy. Neurotoxicology 28:696\u2013697","journal-title":"Neurotoxicology"},{"key":"6653_CR51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000184745","volume":"32","author":"AK Baumgartner","year":"2009","unstructured":"Baumgartner AK, Oberhoffer R, Jacobs VR et al (2009) Reversible foetal cerebral ventriculomegaly and cardiomyopathy under chemotherapy for maternal AML. Onkologie 32:40\u201343","journal-title":"Onkologie"},{"key":"6653_CR52","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jns.2011.05.003","volume":"307","author":"K Hellwig","year":"2011","unstructured":"Hellwig K, Schimrigk S, Chan A, Epplen J, Gold R (2011) A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J Neurol Sci 307:164\u2013165","journal-title":"J Neurol Sci"},{"issue":"Suppl 2","key":"6653_CR53","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1007\/s10072-009-0142-7","volume":"30","author":"V Martinelli","year":"2009","unstructured":"Martinelli V, Radaelli M, Straffi L, Rodegher M, Comi G (2009) Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci 30(Suppl 2):S167\u2013S170","journal-title":"Neurol Sci"},{"key":"6653_CR54","first-page":"CD004454","volume":"3","author":"D Roberts","year":"2006","unstructured":"Roberts D, Dalziel S (2006) Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Sys Rev 3:CD004454","journal-title":"Cochrane Database Sys Rev"},{"key":"6653_CR55","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","volume":"66","author":"JN Hoes","year":"2007","unstructured":"Hoes JN, Jacobs JW, Boers M et al (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Annals Rheumatic Dis 66:1560\u20131567","journal-title":"Annals Rheumatic Dis"},{"key":"6653_CR56","first-page":"431","volume":"6","author":"AB Elliott","year":"2010","unstructured":"Elliott AB, Chakravarty EF (2010) Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Womens Health 6:431\u2013440","journal-title":"Womens Health"},{"key":"6653_CR57","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-004-0495-z","volume":"251","author":"A Achiron","year":"2004","unstructured":"Achiron A, Kishner I, Dolev M et al (2004) Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 251:1133\u20131137","journal-title":"J Neurol"},{"key":"6653_CR58","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/1352458506075654","volume":"13","author":"J Haas","year":"2007","unstructured":"Haas J, Hommes OR (2007) A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 13:900\u2013908","journal-title":"Mult Scler"},{"key":"6653_CR59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1756285608100416","volume":"2","author":"K Hellwig","year":"2009","unstructured":"Hellwig K, Beste C, Schimrigk S, Chan A (2009) Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther Adv Neurol Disord 2:7\u201311","journal-title":"Ther Adv Neurol Disord"},{"key":"6653_CR60","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1212\/WNL.0b013e318224afc9","volume":"77","author":"E Portaccio","year":"2011","unstructured":"Portaccio E, Ghezzi A, Hakiki B et al (2011) Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 77:145\u2013150","journal-title":"Neurology"},{"key":"6653_CR61","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1001\/jama.1988.03720230051029","volume":"259","author":"LM Nelson","year":"1988","unstructured":"Nelson LM, Franklin GM, Jones MC (1988) Risk of multiple sclerosis exacerbation during pregnancy and breast-feeding. JAMA 259:3441\u20133443","journal-title":"JAMA"},{"key":"6653_CR62","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/archneurol.2009.281","volume":"66","author":"K Hellwig","year":"2009","unstructured":"Hellwig K, Haghikia A, Agne H, Beste C, Gold R (2009) Protective effect of breastfeeding in postpartum relapse rate of mothers with multiple sclerosis. Arch Neurol 66:1580\u20131581 (author reply 1581)","journal-title":"Arch Neurol"},{"issue":"Suppl 4","key":"6653_CR63","first-page":"A610","volume":"76","author":"A Jalkanen","year":"2011","unstructured":"Jalkanen A, Airas L, Marttila RJ (2011) To breastfeed or not to breastfeed: effect of breastfeeding on postpartum disease activity in multiple sclerosis revisited. Neurology 76(Suppl 4):A610","journal-title":"Neurology"},{"key":"6653_CR64","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/archneurol.2009.132","volume":"66","author":"A Langer-Gould","year":"2009","unstructured":"Langer-Gould A, Huang SM, Gupta R et al (2009) Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 66:958\u2013963","journal-title":"Arch Neurol"},{"issue":"Suppl 4","key":"6653_CR65","first-page":"A273","volume":"76","author":"K Hellwig","year":"2011","unstructured":"Hellwig K, Kuge M, Gold R, Langer-Gould A (2011) Exclusive breastfeeding reduces the risk of postpartum relapses a prospective study from the German MS and pregnancy registry. Neurology 76(Suppl 4):A273","journal-title":"Neurology"},{"issue":"Suppl 4","key":"6653_CR66","first-page":"A273","volume":"76","author":"K Hellwig","year":"2011","unstructured":"Hellwig K, Haghikia A, Gold R (2011) Multiple sclerosis and pregnancy experience from a nationwide database. Neurology 76(Suppl 4):A273","journal-title":"Neurology"},{"key":"6653_CR67","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s00330-004-2583-y","volume":"15","author":"JA Webb","year":"2005","unstructured":"Webb JA, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) (2005) The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol 15:1234\u20131240","journal-title":"Eur Radiol"},{"issue":"2 Pt 1","key":"6653_CR68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/AOG.0b013e318180a505","volume":"112","author":"MM Chen","year":"2008","unstructured":"Chen MM, Coakley FV, Kaimal A, Laros RK Jr (2008) Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol 112(2 Pt 1):333\u2013340","journal-title":"Obstet Gynecol"},{"key":"6653_CR69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/bfm.2011.0044","volume":"7","author":"TW Hale","year":"2012","unstructured":"Hale TW, Siddiqui AA, Baker TE (2012) Transfer of interferon \u03b2-1a into human breastmilk. Breastfeed Med 7:123\u2013125","journal-title":"Breastfeed Med"},{"key":"6653_CR70","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1586\/14737175.6.12.1823","volume":"6","author":"S Ferrero","year":"2006","unstructured":"Ferrero S, Esposito F, Pretta S, Ragni N (2006) Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding. Exp Rev Neurotherapeutics 6:1823\u20131831","journal-title":"Exp Rev Neurotherapeutics"},{"issue":"Suppl 2","key":"6653_CR71","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1177\/135245850000602S05","volume":"6","author":"J Haas","year":"2000","unstructured":"Haas J (2000) High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler 6(Suppl 2):S18\u2013S20 (discussion S33)","journal-title":"Mult Scler"},{"key":"6653_CR72","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0301-2115(98)00231-0","volume":"82","author":"R Orvieto","year":"1999","unstructured":"Orvieto R, Achiron R, Rotstein Z, Noy S, Bar-Hava I, Achiron A (1999) Pregnancy and multiple sclerosis: a 2-year experience. Eur J Obstet Gynecol Reprod Biol 82:191\u2013194","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"6653_CR73","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/adc.50.11.894","volume":"50","author":"SA McKenzie","year":"1975","unstructured":"McKenzie SA, Selley JA, Agnew JE (1975) Secretion of prednisolone into breast milk. Arch Dis Child 50:894\u2013896","journal-title":"Arch Dis Child"},{"key":"6653_CR74","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0022-3476(85)80259-6","volume":"106","author":"L Ost","year":"1985","unstructured":"Ost L, Wettrell G, Bjorkhem I, Rane A (1985) Prednisolone excretion in human milk. J Pediatrics 106:1008\u20131011","journal-title":"J Pediatrics"},{"key":"6653_CR75","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.1993.28","volume":"53","author":"PA Greenberger","year":"1993","unstructured":"Greenberger PA, Odeh YK, Frederiksen MC, Atkinson AJ Jr (1993) Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Therapeut 53:324\u2013328","journal-title":"Clin Pharmacol Therapeut"},{"key":"6653_CR76","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1191\/1352458504ms1079sr","volume":"10","author":"J Seze de","year":"2004","unstructured":"de Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, Vermersch P (2004) Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 10:596\u2013597","journal-title":"Mult Scler"},{"key":"6653_CR77","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.grf.0000153881.20014.86","volume":"48","author":"KA Bennett","year":"2005","unstructured":"Bennett KA (2005) Pregnancy and multiple sclerosis. Clinical Obstet Gynecol 48:38\u201347","journal-title":"Clinical Obstet Gynecol"},{"key":"6653_CR78","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1055\/s-2007-991127","volume":"27","author":"MK Houtchens","year":"2007","unstructured":"Houtchens MK (2007) Pregnancy and multiple sclerosis. Semin Neurol 27:434\u2013441","journal-title":"Semin Neurol"},{"key":"6653_CR79","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1177\/1352458510372629","volume":"16","author":"A Jalkanen","year":"2010","unstructured":"Jalkanen A, Alanen A, Airas L (2010) Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland. Mult Scler 16:950\u2013955","journal-title":"Mult Scler"},{"key":"6653_CR80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1542-2011.2010.00008.x","volume":"56","author":"M Stuart","year":"2011","unstructured":"Stuart M, Bergstrom L (2011) Pregnancy and multiple sclerosis. J Midwifery Womens Health 56:41\u201347","journal-title":"J Midwifery Womens Health"},{"key":"6653_CR81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejogrb.2003.10.020","volume":"115","author":"S Ferrero","year":"2004","unstructured":"Ferrero S, Pretta S, Ragni N (2004) Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 115:3\u20139","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-012-6653-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-012-6653-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-012-6653-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T05:47:11Z","timestamp":1643262431000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-012-6653-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,25]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["6653"],"URL":"https:\/\/doi.org\/10.1007\/s00415-012-6653-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,25]]}}}